In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Increased carotid wall temperature and thickness in individuals with familial hyperlipidemia syndromes

Session Poster session 2

Speaker Konstantinos Toutouzas

Event : ESC Congress 2016

  • Topic : interventional cardiology and cardiovascular surgery
  • Sub-topic : Interventional Cardiology
  • Session type : Poster Session

Authors : S Galanakos (Athens,GR), K Toutouzas (Athens,GR), I Koutagiar (Athens,GR), J Skoumas (Athens,GR), G Benetos (Athens,GR), A Rigatou (Athens,GR), C Aggeli (Athens,GR), E Siores (Bolton,GB), D Tousoulis (Athens,GR)

S. Galanakos1 , K. Toutouzas1 , I. Koutagiar1 , J. Skoumas1 , G. Benetos1 , A. Rigatou1 , C. Aggeli1 , E. Siores2 , D. Tousoulis1 , 1Hippokration General Hospital, First Department of Cardiology - Athens - Greece , 2University of Bolton - Bolton - United Kingdom ,

European Heart Journal ( 2016 ) 37 ( Abstract Supplement ), 267-268

Background: Adults with familial hyperlipidemia (FH) either heterozygous hypercholesterolemia (hFH) or combined hyperlipidemia (FCH), were characterized by increased LDL levels and accelerated atherosclerosis. Microwave Radiometry (MWR) is a new noninvasive validated method, which allows evaluation of arterial inflammation by measuring differences of temperature within arterial wall.

Purpose: The aim of this pilot study was to determine if there are differences of carotid MWR measurements and morphological characteristics between a) FH individuals and healthy subjects and b) hFH and FCH patients, and how these parameters are affected by treatment for dyslipidemia.

Methods: Fifty-six patients with a recent diagnosis of FH not under statin therapy for at least 6 months and without known cardiovascular disease and 50 age and sex matched healthy subjects were finally recruited. All the subjects underwent assessment of carotid thermal heterogeneity (temperature difference – ΔT) using MWR. Mean common carotid intima-media thickness (ccIMT) was also assessed. FH patients were treated for 6 months with statin or/and ezetimibe and thermal heterogeneity was evaluated after treatment.

Results: In total, 212 carotids from 106 individuals were studied. FH patients showed higher ΔT measurements compared to healthy individuals (0.86±0.42°C vs 0.25±0.11°C, p<0.001). Furthermore, they had increased ccIMT (0.14±0.13 vs 0.07±0.018 mm, p=0.001). There was no significant difference in ΔT measurements and ccIMT between hFH and FCH patients ((0.64±0.32 vs 0.68±0.29oC, p=0.69 and 0.17±0.18 vs 0.11±0.03 mm, p=0.09, respectively). Thermal heterogeneity after 6 months of treatment was reduced statistically significant (0.89±0.4 vs 0.54±0.24°C, p<0.001. Regarding carotid wall thickness, a reduction of ccIMT due to medical therapy was also observed (0.17±0.18 vs 0.11±0.03mm, p=0.09, respectively).

Conclusions: FH patients were characterized by increased carotid wall inflammation and thickness compared to healthy subjects. Thermal heterogeneity in the carotid arteries was positively associated with carotid subclinical atherosclerosis. Dyslipidemia therapy reduced thermal heterogeneity and ccIMT in FH patients implying a beneficial effect of treatment on carotid wall inflammation.

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are